Results 1 to 10 of about 7,836 (163)

Stability of the thromboxane B2 biomarker of low-dose aspirin pharmacodynamics in human whole blood and in long-term stored serum samples [PDF]

Research and Practice in Thrombosis and Haemostasis
Background: Serum thromboxane B2 (sTXB2) is a validated biomarker of low-dose aspirin pharmacodynamics. In the original method, nonanticoagulated blood samples must be incubated at 37 °C immediately after withdrawal, centrifuged and serum supernatant ...
Giovanna Petrucci, Alessandro Rizzi, Simone Bellavia, Francesco Dentali, Giovanni Frisullo, Dario Pitocco, Paola Ranalli, Pier Andrea Rizzo, Irene Scala, Mauro Silingardi, Elisa Zagarrì, Gualberto Gussoni, Bianca Rocca   +12 more
doaj   +2 more sources

Peroxisomal chain-shortening of thromboxane B2: evidence for impaired degradation of thromboxane B2 in Zellweger syndrome

Journal of Lipid Research, 1993
We have shown that rat liver peroxisomes can chain-shorten prostaglandins to dinor- and tetranor-metabolites. In a recent in vivo study we could demonstrate that peroxisomes are of major importance for chain-shortening of prostaglandin F2 alpha in humans
U Diczfalusy, O Vesterqvist, BF Kase, E Lund, SE Alexson   +4 more
doaj   +3 more sources

Body mass index adjusted aspirin dosing does not overcome pharmacokinetic and pharmacodynamic disadvantages in obese pregnant women at risk for preeclampsia: a prospective cohort study [PDF]

Frontiers in Medicine
ObjectiveTo assess if aspirin dosed based on a patient's body mass index (BMI) would yield similar pharmacokinetics and pharmacodynamics for obese compared to non-obese patients who are taking aspirin to prevent preeclampsia.MethodsThis prospective ...
Fulya Sultan Karaduman, Numan Cim, Meltem Caliskan, Bünyamin Cim, Seval Yilmaz Ergani, Filiz Yarsilikal Guleroglu, Ali Cetin   +6 more
doaj   +2 more sources

Aspirin loading in coronary artery disease patients already taking aspirin: A systematic review [PDF]

Journal of Cardiovascular and Thoracic Research
Aspirin is considered a cornerstone medication among patients with established coronary artery disease (CAD). There is a lack of evidence regarding aspirin reloading in CAD patients who are already receiving aspirin therapy.
Hila Asham, Ahmad Separham, Mohammad Javad Kamali, Musab Hama Faraj, Mehdi Maleki, Maryam Mehrpooya, Parvin Sarbakhsh, Taher Entezari-Maleki   +7 more
doaj   +2 more sources

Influence of smoking and smoking cessation on levels of urinary 11-dehydro thromboxane B2 [PDF]

Toxicology Reports, 2018
Background: Thromboxane is a key clinical risk endpoint of smoking-induced inflammation which has been associated in the pathogenesis of cardiovascular disease.
Angela van der Plas, Sandrine Pouly, Guillaume de La Bourdonnaye, Wee Teck Ng, Gizelle Baker, Frank Lüdicke   +5 more
doaj   +2 more sources

Personalized allocation of acetylsalicylic acid therapy for secondary prevention of coronary artery disease

Frontiers in Cardiovascular Medicine, 2022
BackgroundA single-daily dose of 75 mg of acetylsalicylic acid inhibits 100% of thromboxane-B2 synthesis within 30–60 min. Thromboxane-B2 synthesis then recovers slowly as new platelets are released from the bone marrow.
Nischal N. Hegde, Navin Mathew, Rajesh Thachathodiyl, Jaideep C. Menon   +3 more
doaj   +1 more source

Urinary 11‐Dehydro‐Thromboxane B 2 as a Predictor of Acute Myocardial Infarction Outcomes: Results of Leukotrienes and Thromboxane In Myocardial Infarction (LTIMI) Study [PDF]

Journal of the American Heart Association, 2016
Krzysztof Zmudka, Marek Sanak, Marek Tomala   +2 more
exaly   +2 more sources

Calprotectin and platelet aggregation in patients with stable coronary artery disease. [PDF]

PLoS ONE, 2015
Recent studies suggest that the inflammation-associated protein calprotectin may be implicated in the pathogenesis of coronary artery disease (CAD).
Sanne Bøjet Larsen, Erik Lerkevang Grove, Manan Pareek, Steen Dalby Kristensen, Anne-Mette Hvas   +4 more
doaj   +1 more source

Treatment of COVID-19 Pneumonia and Acute Respiratory Distress With Ramatroban, a Thromboxane A2 and Prostaglandin D2 Receptor Antagonist: A Four-Patient Case Series Report

Frontiers in Pharmacology, 2022
Hypoxemia in COVID-19 pneumonia is associated with hospitalization, mechanical ventilation, and mortality. COVID-19 patients exhibit marked increases in fatty acid levels and inflammatory lipid mediators, predominantly arachidonic acid metabolites ...
Martin L. Ogletree, Kate Chander Chiang, Rashmi Kulshrestha, Aditya Agarwal, Aditya Agarwal, Ashutosh Agarwal, Ashutosh Agarwal, Ajay Gupta, Ajay Gupta   +8 more
doaj   +1 more source

Metabolism of thromboxane B2 in the monkey

Journal of Biological Chemistry, 1978
[3H8]Thromboxane B2 was biosynthesized and infused into an unanesthetized monkey. Several urinary metabolites were isolated and their structures elucidated using gas chromatography-mass spectrometry. In addition to the major urinary metabolite, dinor-thromboxane B2, a series of metabolites resulting from dehydrogenetion of the alcohol group at C-11 ...
L J, Roberts, B J, Sweetman, J A, Oates
openaire   +2 more sources